Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03097770

Recruitment Status : Recruiting

First Posted : March 31, 2017

Last Update Posted : December 16, 2019

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Han weidong, Chinese PLA General Hospital

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Actual Primary Completion Date :	May 10, 2019
Estimated Study Completion Date :	April 30, 2020

To Top